Strategic Expansion Leverage the recent acquisition of Pure Diagnostic to cross-sell CLIA-certified molecular diagnostics services, expand geographic reach, and accelerate menu expansion in liquid biopsy based tests across new markets.

Clinical Trial Enablement Position RNA stabilizer tubes and ambient-temperature sample logistics as a differentiator for biotech sponsors and CROs running multicenter trials, highlighting improved specimen integrity and reduced logistics complexity.

AI Powered Diagnostics Target pharmaceutical and biotechnology partners with AI/ML driven mRNA genomic assays for companion diagnostics development, emphasizing path to personalized therapy and potential faster regulatory approvals.

High Trust Credentials Emphasize CLIA certification, CAP accreditation, NYSDOH licensing, and 60+ clinical validations to reassure large health systems and payers about assay accuracy, consistency, and scalability for broader adoption.

Market Differentiation Highlight multi-transcript signatures and liquid biopsy mRNA technology as a unique value proposition for early cancer detection and MRD monitoring to engage health systems pursuing precision oncology leadership.